GondolaBio
The startup is a clinical-stage biopharmaceutical company focused on developing targeted therapeutics for patients with genetic diseases through advanced biological research. By creating medicines that address significant unmet medical needs, the company aims to improve treatment outcomes for rare genetic conditions across various therapeutic areas and stages of development.
- Biotechnology
Funding
Raised to date
$300MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 1 round
CAFLPS+1$300M · Series A
Announced Aug 2024
Disclosed cumulative: $300M
Founders
Founder details are not available yet.
Product
Problem
Many genetic diseases lack effective treatments, leaving patients with significant unmet medical needs. Traditional drug development approaches often struggle to address the complexities of these conditions, resulting in limited therapeutic options.
Solution
GondolaBio is a biopharmaceutical company focused on developing targeted therapeutics for patients with genetic diseases. The company leverages advanced biological research to create medicines that address high unmet needs across various therapeutic areas and stages of development, ranging from early discovery to clinical development. GondolaBio aims to improve treatment outcomes for rare genetic conditions by pioneering breakthroughs in biotech.
Target Audience
The primary target audience includes patients with genetic diseases and the healthcare providers who treat them.
Features
- Focus on developing therapeutics for genetic diseases.
- Utilizes advanced biological research methodologies.
- Targets unmet needs across multiple therapeutic areas.
- Pipeline spans from early discovery to clinical development.